Tiludronate infusion in horses previously submitted to bone scintigraphy

This study was performed to evaluate the systemic short-term effects of tiludronate intravenous infusion on serum biochemical variables when administered as one single-dose in horses that undergo bone scintigraphy within 24 to 36 hours prior to treatment. Thirty-eight horses were enrolled in the stu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dörner,CA, Rick,MC, Judy,CE
Lenguaje:	English
Publicado:	Facultad de Ciencias Veterinarias, Universidad Austral de Chile 2016
Materias:	horse bisphosphonates tiludronate bone scintigraphy
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0301-732X2016000300010
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0301-732X2016000300010
record_format	dspace
spelling	oai:scielo:S0301-732X20160003000102016-12-27Tiludronate infusion in horses previously submitted to bone scintigraphyDörner,CARick,MCJudy,CE horse bisphosphonates tiludronate bone scintigraphy This study was performed to evaluate the systemic short-term effects of tiludronate intravenous infusion on serum biochemical variables when administered as one single-dose in horses that undergo bone scintigraphy within 24 to 36 hours prior to treatment. Thirty-eight horses were enrolled in the study. Fifteen horses received a dose of technetium (0.3 mCi/kg), MDP (20 mg; medronate) and another fifteen horses received technetium (0.3 mCi/kg), MDP (20 mg), and furosemide (1 mg/kg). Then, 24 to 36 hours after the bone scintigraphy, eight horses were selected and received tiludronate (500 mg in 5L of 0.9% NaCl). Blood samples were collected 15 minutes prior, 24 and 48 hours after the treatment and a chemistry panel was assayed on the day of collection. Serum chemistry values were not significantly different between horses receiving tiludronate and those in both control groups. Additionally, one horse showed mild transient signs of colic recorded as pacing and stretching in the stall after 3 hours the injection of the tiludronic acid. The results suggest that tiludronate can be administered safely as one single dose in horses having undergone recent bone scintigraphy without additional complications or detrimental effect other than those previously described for the drug.info:eu-repo/semantics/openAccessFacultad de Ciencias Veterinarias, Universidad Austral de ChileArchivos de medicina veterinaria v.48 n.3 20162016-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0301-732X2016000300010en10.4067/S0301-732X2016000300010
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	horse bisphosphonates tiludronate bone scintigraphy
spellingShingle	horse bisphosphonates tiludronate bone scintigraphy Dörner,CA Rick,MC Judy,CE Tiludronate infusion in horses previously submitted to bone scintigraphy
description	This study was performed to evaluate the systemic short-term effects of tiludronate intravenous infusion on serum biochemical variables when administered as one single-dose in horses that undergo bone scintigraphy within 24 to 36 hours prior to treatment. Thirty-eight horses were enrolled in the study. Fifteen horses received a dose of technetium (0.3 mCi/kg), MDP (20 mg; medronate) and another fifteen horses received technetium (0.3 mCi/kg), MDP (20 mg), and furosemide (1 mg/kg). Then, 24 to 36 hours after the bone scintigraphy, eight horses were selected and received tiludronate (500 mg in 5L of 0.9% NaCl). Blood samples were collected 15 minutes prior, 24 and 48 hours after the treatment and a chemistry panel was assayed on the day of collection. Serum chemistry values were not significantly different between horses receiving tiludronate and those in both control groups. Additionally, one horse showed mild transient signs of colic recorded as pacing and stretching in the stall after 3 hours the injection of the tiludronic acid. The results suggest that tiludronate can be administered safely as one single dose in horses having undergone recent bone scintigraphy without additional complications or detrimental effect other than those previously described for the drug.
author	Dörner,CA Rick,MC Judy,CE
author_facet	Dörner,CA Rick,MC Judy,CE
author_sort	Dörner,CA
title	Tiludronate infusion in horses previously submitted to bone scintigraphy
title_short	Tiludronate infusion in horses previously submitted to bone scintigraphy
title_full	Tiludronate infusion in horses previously submitted to bone scintigraphy
title_fullStr	Tiludronate infusion in horses previously submitted to bone scintigraphy
title_full_unstemmed	Tiludronate infusion in horses previously submitted to bone scintigraphy
title_sort	tiludronate infusion in horses previously submitted to bone scintigraphy
publisher	Facultad de Ciencias Veterinarias, Universidad Austral de Chile
publishDate	2016
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0301-732X2016000300010
work_keys_str_mv	AT dornerca tiludronateinfusioninhorsespreviouslysubmittedtobonescintigraphy AT rickmc tiludronateinfusioninhorsespreviouslysubmittedtobonescintigraphy AT judyce tiludronateinfusioninhorsespreviouslysubmittedtobonescintigraphy
_version_	1718437970683363328

Tiludronate infusion in horses previously submitted to bone scintigraphy

Ejemplares similares